

Stock Sentiment Analysis Report

Illumina (ILMN)

Analysis Period: 2026-03-14 to 2026-04-13 (30 days)

Generated: 2026-04-13 10:07:03

Executive Summary


Sentiment analysis for Illumina (ILMN) from 2026-03-14 to 2026-04-13. Analyzed 169 items across FDA and news sources.

Sentiment Breakdown

Category	Count	Percentage
Positive	47	27.8%
Negative	64	37.9%
Neutral	58	34.3%
Total	169	100.0%

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

Title	Source	Date	Score
Due persone che si appartengono lo sanno, lo capis...	news	2026-04-11	0.909
The weak point: Why pharmaceutical security belong...	news	2026-04-10	0.900
Evolution of a truncated nucleocapsid protein enha...	news	2026-04-01	0.869
Molecular Tumor Board Solutions Market Outlook 202...	news	2026-04-07	0.832
Artificial Intelligence in Oncology: Assessment of...	news	2026-03-30	0.799

Top Negative Events

Title	Source	Date	Score
Single-cell transcriptome profiling reveals herpes...	news	2026-04-02	-1.000
DNMT1 loss leads to hypermethylation of a subset o...	news	2026-04-02	-0.984
Bacteria producing the bioplastic polyhydroxybutyr...	news	2026-04-10	-0.917
I tried the next frontier in cancer screening. I'm...	news	2026-04-09	-0.906
Biobanking of gynecologic cancer biospecimens: Dev...	news	2026-03-31	-0.869